Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
Approximately 50% of patients with psychiatric disorders do not fully adhere to the prescribed psychopharmacological therapy, significantly impacting the progression of the disorder and the patient's quality of life. The present study aimed to assess potential differences in terms of rates and clinical features of treatment adherence in a large cohort of psychiatric patients with different diagnoses attending various psychiatric services. The study included 307 psychiatric patients diagnosed with a primary major depressive disorder, bipolar disorder, anxiety disorder, schizophrenic spectrum disorder, or personality disorder. Patient's adherence to treatment was evaluated using the Clinician Rating Scale, with a cutoff of at least five defining adherence subgroups. One-third of the sample reported poor medication adherence. A lower rate of adherence emerged among patients with schizophrenic spectrum disorder and bipolar disorder. Subjects with poor adherence were more frequently inpatients and showed higher current substance use, a greater number of previous hospitalizations, and more severe scores at psychopathological assessment compared with patients with positive adherence. Poor adherence was associated with symptom severity and increased rates of relapses and rehospitalizations. In addition, substance use appears to be an unfavorable transdiagnostic factor for treatment adherence.
Identifiants
pubmed: 38813934
doi: 10.1097/YIC.0000000000000557
pii: 00004850-990000000-00140
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Akerblad AC, Bengtsson F, von Knorring L, Ekselius L (2006). Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 21:117–124.
Akerblad A-C, Bengtsson F, Holgersson M, von Knorring L, Ekselius L (2008). Identification of primary care patients at risk of nonadherence to antidepressant treatment. Patient Prefer Adherence 2:379–386.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Publishing: 2013.
Arvilommi P, Suominen K, Mantere O, Leppämäki S, Valtonen H, Isometsä E (2014). Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study. J Affect Disord 155:110–117.
Baeza-Velasco C, Olié E, Béziat S, Guillaume S, Courtet P (2018). Determinants of suboptimal medication adherence in patients with a major depressive episode. Depress Anxiety 36:244–251.
Barbuti M, Maiello M, Spera V, Pallucchini A, Brancati GE, Maremmani AGI, et al. (2023). Challenges of treating ADHD with comorbid substance use disorder: considerations for the clinician. J Clin Med 12:3096.
Barkhof E, Meijer CJ, de Sonneville LMH, Linszen DH, de Haan L (2012). Interventions to improve adherence to antipsychotic medication in patients with schizophrenia– a review of the past decade. Eur Psychiatry 27:9–18.
Benatti B, Girone N, Conti D, Cocchi M, Achilli F, Leo S, et al. (2023). The role of lifestyle on adherence to treatment in a sample of patients with unipolar and bipolar depression. Int J Environ Res Public Health 20:1994.
Bloomfield MAP, Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75:470–478.
Bobo WV (2017). The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc 92:1532–1551.
Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L (2015). Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 11:2125–2142.
Brancati GE, De Dominicis F, Petrucci A, Pallucchini A, Carli M, Medda P, et al. (2023). Long-term treatment of adult ADHD in a naturalistic setting: clinical predictors of attrition, medication choice, improvement, and response. World J Biol Psychiatry 24:523–538.
Burton WN, Chen C-Y, Conti DJ, Schultz AB, Edington DW (2007). The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 13:105–112.
Byerly MJ, Nakonezny PA, Lescouflair E (2007). Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 30:437–452.
Cañas F, Alptekin K, Azorin JM, Dubois V, Emsley R, García AG, et al. (2013). Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig 33:97–107.
Colizzi M, Carra E, Fraietta S, Lally J, Quattrone D, Bonaccorso S, et al. (2016). Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res 170:311–317.
Colom F, Vieta E (2002). Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatr Scand 105:161–163.
Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C (2000). Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 61:549–555.
Cramer JA, Rosenheck R (1998). Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201.
Dell’Osso B, Albert U, Carrà G, Pompili M, Nanni MG, Pasquini M, et al. (2020). How to improve adherence to antidepressant treatments in patients with major depression: a psychoeducational consensus checklist. Ann Gen Psychiatry 19:61.
Doesschate MC, Bockting CL, Koeter MW, Schene AH (2009). Predictors of nonadherence to continuation and maintenance antidepressant medication in patients with remitted recurrent depression. J Clin Psychiatry 70:63–69.
Egglefield K, Cogan L, Leckman-Westin E, Finnerty M (2020). Antipsychotic medication adherence and diabetes-related hospitalizations among medicaid recipients with diabetes and schizophrenia. Psychiatr Serv 71:236–242.
Faridi K, Joober R, Malla A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophr Res 141:78–82.
Farooq S, Naeem F (2014). Tackling nonadherence in psychiatric disorders: current opinion. Neuropsychiatr Dis Treat 10:1069–1077.
Garcìa S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, et al. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:355–371.
Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. (2006). Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8:618–624.
Gudjonsson GH, Main N (2008). How are personality disorders related to compliance? J Forens Psychiatry Psychol 19:180–190.
Haddad PM, Brain C, Scott J (2014). Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5:43–62.
Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50–55.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
Hicks PL, Mulvey KP, Chander G, Fleishman JA, Josephs JS, Korthuis PT, et al.; HIV Research Network (2007). The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care 19:1134–1140.
Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M (2013). Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 3:200–218.
Higgins ST (2019). Behavior change, health, and health disparities 2019: opioids, tobacco, and treatment adherence. Prev Med 128:105887.
Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, et al. (2010). Nonadherence to medication four years after a first episode of psychosis and associated risk factors. Psychiatr Serv 61:189–192.
Holma IA, Holma KM, Melartin TK, Isometsä ET (2010). Treatment attitudes and adherence of psychiatric patients with major depressive disorder: a five-year prospective study. J Affect Disord 127:102–112.
Hong J, Reed C, Novick D, Haro JM, Aguado J (2011). Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 190:110–114.
Howes OD, Thase ME, Pillinger T (2022). Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 27:58–72.
Iuso S, Severo M, Trotta N, Ventriglio A, Fiore P, Bellomo A, et al. (2023). Improvements in treatment adherence after family psychoeducation in patients affected by psychosis: preliminary findings. J Pers Med 13:1437.
Karpov B, Joffe G, Aaltonen K, Oksanen J, Suominen K, Melartin T, et al. (2018). Self-reported treatment adherence among psychiatric in- and outpatients. Nord J Psychiatry 72:526–533.
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
Kemp R, David A (1996). Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 169:444–450.
Kemp R, Kirov G, Everitt B, Hayward P, David A (1998). Randomised controlled trial of compliance therapy. Br J Psychiatry 172:413–419.
Lambert M, Conus P, Cotton S, Robinson J, McGorry PD, Schimmelmann BG (2010). Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol 30:565–572.
Leclerc E, Noto C, Bressan RA, Brietzke E (2015). Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Braz J Psychiatry 37:168–176.
Llorca PM (2008). Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 161:235–247.
MacDonald L, Chapman S, Syrett M, Bowskill R, Horne R (2016). Improving medication adherence in bipolar disorder: a systematic review and meta-analysis of 30 years of intervention trials. J Affect Disord 194:202–221.
Mak KY, Lo WT, Yeung WS, Wong M, Chung WS, Chui E, et al. (2014). Consensus statements on adherence issues in schizophrenia for Hong Kong. Asian J Psychiatr. 12:163–169.
Mert DG, Turgut NH, Kelleci M, Semiz M (2015). Perspectives on reasons of medication nonadherence in psychiatric patients. Patient Prefer Adherence 9:87–93.
Meyer P (2004). Consumer representation in multi-site HIV, mental health, and substance abuse research: the HIV/AIDS treatment adherence, health outcomes and cost study. AIDS Care 16:137–153.
Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D (2009). A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 113:138–144.
Mirhaj Mohammadabadi MS, Mohammadsadeghi H, Eftekhar Adrebili M, Partovi Kolour Z, Kashaninasab F, Rashedi V, et al. (2022). Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder. Front Psychiatry 13:1056050.
Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated Treatment for Dual Disorders: A Guide to Effective Practice. Guilford Press: 2003
Murray RM, Mehta M, Di Forti M (2014). Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. Biol Psychiatry 75:430–431.
Overall JE, Gorham DR (1988). The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 24:97–99.
Phillips ML, Kupfer DJ (2013). Bipolar disorder diagnosis: challenges and future directions. Lancet 381:1663–1671.
Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A (2013). The influence of perceived social support on medication adherence in first-episode psychosis. Can J Psychiatry 58:59–65.
Rekha R, Masroor J, Sushma K, et al. (2005). Reasons for drug non-compliance of psychiatric patients. J Indian Acad Appl Psychol 31:24–28.
Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV (2006). Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 8:232–241.
Scott J, Pope M (2002). Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 63:384–390.
Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A (2020). Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev 9:17.
Smith F, Clifford S (2011). Adherence to medication among chronic patients in Middle Eastern countries: review of studies. East Mediterr Health J 17:356–363.
Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, et al. (2017). A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One 12:e0170651.
Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, et al. (2011). Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 168:286–292.
Taj F, Tanwir M, Aly Z, Khowajah AA, Tariq A, Syed FK, et al. (2008). Factors associated with non-adherence among psychiatric patients at a tertiary care hospital, Karachi, Pakistan: a questionnaire based cross-sectional study. J Pak Med Assoc 58:432–436.
Weiden PJ (2007). Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 68(Suppl 14):14–19.
Wingerson D, Sullivan M, Dager S, Flick S, Dunner D, Roy-Byrne P (1993). Personality traits and early discontinuation from clinical trials in anxious patients. J Clin Psychopharmacol 13:194–197.
World Health Organization. Adherence to Long-term Therapies: Evidence for Action: WHO; 2003. p. 3. https://iris.who.int/handle/10665/42682
Wu J, DeWalt DA, Baker DW, Schillinger D, Ruo B, Bibbins-Domingo K, et al. (2013). A single-item self-report medication adherence question predicts hospitalisation and death in patients with heart failure. J Clin Nurs 23:2554–2564.
Xiao J, Mi W, Li L, Shi Y, Zhang H (2015). High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1161–1167.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20:97–170.
Yee CS, Hawken ER, Baldessarini RJ, Vázquez GH (2019). Maintenance pharmacological treatment of juvenile bipolar disorder: review and meta-analyses. Int J Neuropsychopharmacol 22:531–540.
Young RC, Biggs JT, Ziegler VE, Meyer DAA (1978). rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
Zhang G, Patel K, Moghe A, Reid A, Serper M, Calgaro L, et al. (2019). Provider perceptions of hepatitis c treatment adherence and initiation. Dig Dis Sci 65:1324–1333.